Molecular Therapy-Oncolytics

Papers
(The TQCC of Molecular Therapy-Oncolytics is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence187
Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering143
Ferroptosis gene signature in cholangiocarcinoma121
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models90
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy70
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation68
Promoting role of pentraxin-3 in esophageal squamous cell carcinoma67
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis58
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 154
Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo54
A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy52
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML51
Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy50
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model49
Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq48
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers44
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma42
lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC40
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy40
Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA40
The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer39
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity36
PROTACs in gastrointestinal cancers36
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer35
Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma34
AAMP promotes colorectal cancer metastasis by suppressing SMURF2-mediated ubiquitination and degradation of RhoA33
Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma33
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme32
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma30
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response29
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T28
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity28
Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma28
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy27
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer27
Current development in adenoviral vectors for cancer immunotherapy26
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia26
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia26
A library of cancer testis specific T cell receptors for T cell receptor gene therapy26
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges25
Cannabinoid receptors promote chronic intermittent hypoxia-induced breast cancer metastasis via IGF-1R/AKT/GSK-3β25
Radiovirotherapy at twenty25
RETRACTED: Comprehensive analysis of FKBP4/NR3C1/TMEM173 signaling pathway in triple-negative breast cancer cell and dendritic cell among tumor microenvironment24
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum24
Human lung adenocarcinoma CD47 is upregulated by interferon-γ and promotes tumor metastasis24
Adding recombinant AAVs to the cancer therapeutics mix24
Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma24
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products24
A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer24
LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex24
Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade24
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?23
Thank you to our 2021 reviewers23
Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers23
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma22
Thank you to our 2023 reviewers22
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?22
Oncolytic adenovirus for treatment of malignant ascites22
Non-coding RNAs and glioma: Focus on cancer stem cells22
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression22
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice22
DNA-damaging cancer cells to improve virotherapy22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities21
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers21
Exosomal and intracellular miR-320b promotes lymphatic metastasis in esophageal squamous cell carcinoma21
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory21
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis21
Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis20
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape20
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells20
TTN-AS1 accelerates the growth and migration of nasopharyngeal carcinoma cells via targeting miR-876-5p/NETO220
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response20
Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene20
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy20
Sodium iodide symporter-targeted gene therapy in glioblastoma20
Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy19
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo19
Exploring the potential of eRNAs in cancer immunotherapy19
Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution19
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon19
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering19
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas19
Comprehensive landscape of tRNA-derived fragments in lung cancer19
A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer19
Advancing together and moving forward: Combination gene and cellular immunotherapies19
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives19
0.11261415481567